An evaluation of Debrisoft® Duo was undertaken at Accelerate, a Community Interest Company (CIC), over a period of three months in 2025. This evaluation was undertaken independently by the clinical team, which included seven clinicians across three sites. Thirty patients participated in the project, presenting with a variety of aetiologies including venous leg ulceration, hyperkeratosis and non-diabetic foot ulceration. This resulted in 102 episodes of mechanical debridement across the cohort. Data was collected using e-Kare inSight®, pre- and post-debridement. This was enhanced by feedback from participants. Key findings included average time to debride which was two to four minutes, in >98% of the episodes clinicians identified visible changes within two minutes, the average reduction in devitalised tissue was 29, and clinicians reported the new Debrisoft Duo was more eͿective than the standard Debrisoft® debridement pad.